Skip to main content
. 2014 Jun 18;34(9):1531–1539. doi: 10.1038/jcbfm.2014.113

Figure 5.

Figure 5

Effect of Akt (protein kinase B) inhibitor viii and rapamycin on cognitive outcome after sham or closed head injury (CHI). (A, B) Sham injured mice (n=10/group) were administered Akt inhibitor viii (Akt viii), rapamycin (Rap), or vehicle (Veh) intracerebroventricularly and Morris water maze testing was performed 3 days later. Although all sham-injured groups learned the task (P<0.001 for time, hidden and visible platform trials), no differences in hidden (P=0.37 for group, repeated-measures ANOVA (RM ANOVA)) or visible platform (P=0.16 for group, RM ANOVA), or probe trials (P=0.4 ANOVA, B) were observed. (C, D) Of the CHI groups (n=18/group), all mice learned the hidden platform paradigms (P<0.001 for time in each group). In the RM ANOVA used to evaluate treatment effects there was a significant group effect (P=0.0031). In post hoc analyses, rapamycin-treated mice performed significantly worse than vehicle-treated mice in hidden platform (P<0.01 Dunnett's test) and probe trials (P<0.05 ANOVA and *P<0.05 Dunnett's test, D). No differences in visible platform performance were noted among CHI groups (P=0.71 for group) and no differences in hidden, visible platform, or probe trials were noted between CHI-VEH and CHI-Akt viii groups.